Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.022x

Based on the latest financial reports, Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) has a cash flow conversion efficiency ratio of 0.022x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥68.66 Million ≈ $10.05 Million USD) by net assets (CN¥3.13 Billion ≈ $458.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Sinopep-Allsino Biopharmaceutical Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Sinopep-Allsino Biopharmaceutical Co. Lt for a breakdown of total debt and financial obligations.

Sinopep-Allsino Biopharmaceutical Co. Ltd. A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sinopep-Allsino Biopharmaceutical Co. Ltd. A ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Black Box Limited NSE:BBOX	0.059x
Suzhou Hailu Heavy Industry Co Ltd SHE:002255	0.055x
LS Materials KQ:417200	0.016x
O-I Glass Inc NYSE:OI	0.174x
Concord Biotech Limited NSE:CONCORDBIO	N/A
Kelt Exploration Ltd. TO:KEL	0.048x
Happy Forgings Limited NSE:HAPPYFORGE	0.018x
Enovis Corp NYSE:ENOV	0.059x

Annual Cash Flow Conversion Efficiency for Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2024)

The table below shows the annual cash flow conversion efficiency of Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Sinopep-Allsino Biopharmaceutical Co. Lt (688076) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥2.68 Billion ≈ $392.51 Million	CN¥400.12 Million ≈ $58.55 Million	0.149x	-6.75%
2023-12-31	CN¥2.19 Billion ≈ $320.36 Million	CN¥350.21 Million ≈ $51.25 Million	0.160x	+951.19%
2022-12-31	CN¥1.92 Billion ≈ $281.67 Million	CN¥29.29 Million ≈ $4.29 Million	0.015x	-84.77%
2021-12-31	CN¥1.81 Billion ≈ $264.68 Million	CN¥180.75 Million ≈ $26.45 Million	0.100x	-31.72%
2020-12-31	CN¥966.02 Million ≈ $141.36 Million	CN¥141.38 Million ≈ $20.69 Million	0.146x	+166.14%
2019-12-31	CN¥838.98 Million ≈ $122.77 Million	CN¥46.14 Million ≈ $6.75 Million	0.055x	-55.04%
2018-12-31	CN¥785.38 Million ≈ $114.93 Million	CN¥96.06 Million ≈ $14.06 Million	0.122x	+253.60%
2017-12-31	CN¥321.20 Million ≈ $47.00 Million	CN¥11.11 Million ≈ $1.63 Million	0.035x	+105.51%
2016-12-31	CN¥34.95 Million ≈ $5.11 Million	CN¥-21.95 Million ≈ $-3.21 Million	-0.628x	+59.12%
2015-12-31	CN¥73.32 Million ≈ $10.73 Million	CN¥-112.62 Million ≈ $-16.48 Million	-1.536x	+51.62%
2014-12-31	CN¥-21.47 Million ≈ $-3.14 Million	CN¥68.18 Million ≈ $9.98 Million	-3.175x	-126.79%
2013-12-31	CN¥3.69 Million ≈ $539.29K	CN¥43.67 Million ≈ $6.39 Million	11.850x	--

About Sinopep-Allsino Biopharmaceutical Co. Ltd. A

SHG:688076 China Biotechnology

Market Cap

$1.38 Billion

CN¥9.45 Billion CNY

Market Cap Rank

#7749 Global

#1920 in China

Share Price

CN¥29.90

Change (1 day)

+0.57%

52-Week Range

CN¥28.42 - CN¥56.90

All Time High

CN¥90.43